Home › NCT04615546

Role of Nutrient Transit in Hyperinsulinemic Hypoglycemia

Role of Nutrient Transit and Incretin Hormones in Hyperinsulinemic Hypoglycemia

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Male or female patients 18-70 years of age
* Post-bariatric surgery more than 6 months prior to signing the informed consent (not required for non-surgical controls)
* Documented history of hyperinsulinemic hypoglycemia (not required for post-bariatric and non-surgical controls)

Exclusion Criteria:

* Patients currently using sulfonylureas or other medications that may interfere with glucose metabolism within 5 half-lives of drug.
* Participation in any clinical investigation within 4 weeks prior to dosing
* History of or current insulinoma
* Active infection or significant acute illness within 2 weeks prior to dosing
* Female patients who are pregnant or lactating
* Women of childbearing potential and not utilizing effective contraceptive methods
* Inadequate end organ function as defined by: Serum creatinine \>2.0 mg/dL, alanine transaminase (ALT) and aspartate aminotransferase (AST) \> 2 x Upper Normal Limit
* Allergy to test meal or medications used in the study

About the study

Severe hypoglycemia (low blood sugar)after gastric bypass surgery is an increasingly recognized condition, characterized by symptoms of hypoglycemia after eating and inappropriately elevated insulin concentrations that occur at the time of hypoglycemia. Severe hypoglycemia can be dangerous and debilitating and can also impact cognitive function. At the moment no medical therapies have been developed for this disorder. Determining why some but not other patients develop this condition would allow for improved prediction, prevention, and treatment approaches. The purpose of the study is to understand the physiological changes observed in those patients who undergo gastric bypass and develop symptomatic hypoglycemia.

What is being tested

• Use of Continuous Glucose Monitor (CGM) (behavioral)
• Use of "Cardea Solo" monitoring (other)

Sponsor: Stanford University · Participants: 60 · Started: May 6, 2020

Contact the study team

Official record on ClinicalTrials.gov — NCT04615546

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.